Company: SUPN
Filing Date: 2025-05-28
Form Type: 8-K
Source: 0001356576-25-000038
Chunk: 0

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-05-28
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01

Other Events.

On May 28, 2025, Supernus Pharmaceuticals, Inc. (the “ Company”) issued a press release announcing that on May 22, 2025 and May 23, 2025, it received a Paragraph IV Notice Letters from third parties notifying Supernus that the third parties submitted an Abbreviated New Drug Applications (ANDA) for viloxazine hydrochloride capsules, eq. 100, 150, and 200 mg base. Supernus is currently reviewing the details of these Notice Letters and intends to vigorously enforce its intellectual property rights relating to Qelbree®. The U. S. Food and Drug Administration’s Orange Book currently lists six issued United States patents as covering Qelbree, three that expire in September 2029, two that expire in February 2033 and one that expires in April 2035.

A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.